Inve India ▾

Aster DM Healthcare share price & results

Aster DM Healthcare Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

South India hospital chain running multi-specialty hospitals, clinics, diagnostic labs & franchise pharmacies

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,311 ₹ crore+21.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin20.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit29.0 ₹ crore−69.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity9.99 %+6.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.86 %+2.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)15.71 %+0.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 9 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Aster DM Healthcare Limited management guidance track record on Inve: 21 targets tracked across analysed earnings calls (5 achieved, 4 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Pharmacy Business BreakevenBreakeven in Q4 FY26
Call transcript, Q3 FY25 · 3 Feb 2025		Q3 FY25Q1 FY27:Already achieved in prior quarters.
Call transcript, Q1 FY27 · 5 Aug 2026		Achieved
Aster Labs EBITDA MarginMore than 20% margin in next 2-3 years
Call transcript, Q3 FY26 · 9 Feb 2026		Q3 FY26Q1 FY27:Not mentioned in Q1 FY27 commentary.
Call transcript, Q1 FY27 · 5 Aug 2026		Ghosted
ARPOB / ARPP Growth7-8% going forward
Call transcript, Q4 FY25 · 21 May 2025		Q4 FY25Q1 FY27:Combined ARPP/ARPOB growth not explicitly stated; implied growth of ~6.2% YoY is below the 7-8% target.
Call transcript, Q1 FY27 · 5 Aug 2026		At Risk

Source: Inve Guidance Tracker for Aster DM Healthcare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Aster DM Healthcare Limited's 21 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹662.8 +2.44% · +₹15.8

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −6.1% 1Y

₹600₹700₹800Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025Q3 FY26 — 9 Feb 2026Q4 FY26 — 30 Apr 2026Q1 FY27 — 5 Aug 2026

1Y: ₹705.8 on 24 Oct 2025 → ₹662.8. High ₹869.7 (7 Aug 2026), low ₹537.95 (5 Feb 2026).

Previous close
₹647
Market cap
₹57.7k Cr
52-week range
₹537.95 – ₹869.7
One year
−5.02%
Price to earnings (TTM to Jun 2026)
159.20×
Return on equity (TTM to Jun 2026)
9.99%

Overview

Symbol
NSE:ASTERDM
Exchange
NSE
Currency
INR

What Aster DM Healthcare Limited does

Based on the company's own presentations, annual report and earnings calls.

Aster DM Healthcare operates a network of multi-specialty tertiary and quaternary care hospitals, clinics, diagnostic labs and Patient Experience Centres (PECs) across South India under hospital brands including Aster, MIMS (Malabar Institute of Medical Sciences) and Ramesh Hospitals. It earns primarily from inpatient and outpatient hospital care, complex specialty procedures (cardiac, oncology, transplants, robotic-assisted surgery) and a diagnostics/labs business, supplemented by a chain of Aster-branded retail pharmacies operated under license by Aster Retail Pharmacy Private Limited (ARPPL). The company follows a cluster-based expansion model across under-served cities and is in the process of merging with Blackstone-backed Quality Care India Limited (QCIL) — owner of the CARE Hospitals, KIMSHealth and Evercare hospital brands — a deal expected to create one of India's top-three hospital chains once completed.

Segments

  • Hospitals & Clinics
  • Labs
  • Pharmacy (franchise)
Operational bed capacity
5,449 beds
Hospitals
19
Cities of presence
15
States of presence
5 (Kerala, Karnataka, Maharashtra, Andhra Pradesh, Telangana)
Labs & Patient Experience Centres (PECs)
262
Franchise pharmacies (Aster-branded)
203
Employees 20,458 (FY2024-25 (as of March 3) Company website

How the price took the results

close before → close after

Q1 FY27
+0.9%
5 Aug
Q4 FY26
+6.2%
1 May
Q3 FY26
+1.6%
9 Feb
Q2 FY26
+0.8%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Aster DM Healthcare Limited

Free account: one company. Everything above stays public.

Write why you follow Aster DM Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Aster DM Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.